Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.96% | -32.19% | -44.74% | 49.64% | 9,803.52% |
| Total Depreciation and Amortization | 11.13% | 15.00% | 16.08% | 16.48% | 18.30% |
| Total Amortization of Deferred Charges | -30.51% | -18.67% | -14.72% | -50.59% | -65.23% |
| Total Other Non-Cash Items | 214.40% | 284.89% | 167.41% | 154.65% | 135.28% |
| Change in Net Operating Assets | -1,604.24% | -81.58% | 55.61% | -57.18% | -103.29% |
| Cash from Operations | -20.34% | -14.39% | -10.95% | 71.88% | 693.39% |
| Capital Expenditure | -88.71% | -78.82% | -66.48% | -65.04% | -65.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | -100.00% |
| Other Investing Activities | -64.21% | -132.55% | -217.01% | -37.09% | 37.07% |
| Cash from Investing | -86.93% | -132.74% | -203.92% | -239.43% | -345.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | -12.84% | -59.47% | -71.87% | -76.87% | -80.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 18.13% | -127.58% | -105,219.05% | -14,399.22% | -6,317.80% |
| Cash from Financing | 11.57% | -34.16% | -72.34% | 43.53% | 72.05% |
| Foreign Exchange rate Adjustments | 59.25% | -140.74% | -157.56% | -658.00% | -132.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.19% | -28.19% | -32.56% | 483.21% | 247.77% |